Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women

NCT ID: NCT03767803

Last Updated: 2020-01-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

344 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-01

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Whole blood sample procurement study from pregnant women with signs and symptoms of Preeclampsia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This multicenter non-interventional observational sample acquisition study is designed to acquire whole-blood samples from pregnant women who present with signs and symptoms of Pre-E and are in the care at an OB-GYN and/or Maternal Fetal Medicine (MFM) site, defined as outpatient centers, clinic sites, and medical offices.

Study population includes subjects who are pregnant, of any race or ethnicity, 18 to 45 years of age, 28 0/7 to 36 6/7 weeks' gestational age with a singleton fetus and have provided written informed consent to provide whole blood specimens at one or more study visits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Eclampsia Hypertension Proteinuria in Pregnancy Thrombocytopenia Renal Insufficiency Impaired Liver Function Pulmonary Edema Headache Visual Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Positive Preeclampsia group

A group with diagnosis of preeclampsia within 24 hours of testing and pre-term delivery

Non-interventional study

Intervention Type OTHER

This is an observational, non-interventional study.

Study Cohort

A group without diagnosis of preeclampsia. Also includes a group without diagnosis of preeclampsia within 24 hours of testing, but who have subsequent worsening or re-emergence of signs and symptoms of preeclampsia, and are later diagnosed with preeclampsia and have pre-term delivery.

Non-interventional study

Intervention Type OTHER

This is an observational, non-interventional study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-interventional study

This is an observational, non-interventional study.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject is 18 to 45 years of age
* Subject is willing to provide informed consent
* Subject enrolling at a study OB-GYN or MFM site is in the opinion of the physician able to provide 20 mL of whole blood and will comply with all study procedures
* Subject has a singleton fetus of 28 0/7 to 36 6/7 weeks' gestational age using 2014 ACOG Dating Criteria (pregnancies starting as twins but complicated with either vanishing twin syndrome or fetal demise of one twin before 14 weeks, are eligible for inclusion)
* Patient presenting with clinical suspicion of Pre-E based on one or more of the following clinical signs and symptoms of Pre-E:

* New onset increased blood pressure in otherwise normotensive patient
* Worsening hypertension in a patient with pre-existing hypertension
* New onset proteinuria or worsening of pre-existing proteinuria
* Any other clinical finding typically associated with suspicion of Pre-E and requiring workup to rule-out Pre-E

Exclusion Criteria

* Pregnancy is non-viable, as evidenced by absence of fetal cardiac activity
* Major fetal anomaly or chromosomal aneuploidy
* Current dialysis for kidney failure, including continuous ambulatory peritoneal dialysis
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Progenity, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Stiegler, PhD

Role: STUDY_DIRECTOR

Progenity, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

West Coast Medical Research, Inc.

San Diego, California, United States

Site Status

Christiana Care

Newark, Delaware, United States

Site Status

Women's Health Partners, LLC

Boca Raton, Florida, United States

Site Status

Discovery Clinical Research

Plantation, Florida, United States

Site Status

Leavitt Clinical Research

Idaho Falls, Idaho, United States

Site Status

Norton Healthcare

Louisville, Kentucky, United States

Site Status

Obstetrics and Gynecology Associates AMB

Silver Spring, Maryland, United States

Site Status

Valley OB-GYN Clinic, PC

Saginaw, Michigan, United States

Site Status

Rutgers-RWJMS

New Brunswick, New Jersey, United States

Site Status

St. Peter's University Hospital

New Brunswick, New Jersey, United States

Site Status

Virtua Voorhees Hospital

Voorhees Township, New Jersey, United States

Site Status

New Life Medical Esthetics and Wellness, PLLC

Brooklyn, New York, United States

Site Status

Columbia University

New York, New York, United States

Site Status

Total Woman Care

Elkin, North Carolina, United States

Site Status

David B. Schwartz, MD, LLC

Cincinnati, Ohio, United States

Site Status

Obstetrics & Gynecology Associates, Inc.

Fairfield, Ohio, United States

Site Status

Hilltop Obstetrics & Gynecology

Franklin, Ohio, United States

Site Status

Dr. Ahuja and Associates OB-GYN

Mentor, Ohio, United States

Site Status

Drexel University

Philadelphia, Pennsylvania, United States

Site Status

The Jackson Clinic, PA

Jackson, Tennessee, United States

Site Status

Aa Ob-Gyn, Pllc

Austin, Texas, United States

Site Status

OB-GYN North

Austin, Texas, United States

Site Status

Corpus Christi Women's Clinic

Corpus Christi, Texas, United States

Site Status

Advanced Clinical Research

Salt Lake City, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PRO-129-PREECLAMPSIA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.